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Context:High plasma triglycerides (TG) have been shown to be independent and better predictors
of cardiovasculardisease than low-density lipoprotein (LDL) cholesterol inwomen. Thismaybedue
to gender differences in very-low-density lipoprotein 1 (VLDL1)- and VLDL2-TG and fatty acid
kinetics.
Objective:Our objective was to investigate whether there are differences in VLDL1- and VLDL2-TG
and fatty acid kinetics in obese men and postmenopausal women, a high risk group for cardio-
vascular disease.
ResearchDesign andMethods: Stable isotopes techniqueswere used tomeasure fasting palmitate
rate of appearance, metabolic clearance rate, oxidation rate, and nonoxidative disposal rate,
VLDL1-TG and VLDL2-TG fractional catabolic rate (FCR) and production rate (PR). Whole-body fat
distribution was measured by magnetic resonance imaging.
Participants: Participants included 10 postmenopausal obese women and eight obese men
matched for age, body mass index, and fasting plasma TG.
Results: Thewomenhad lower visceral fat andhigher sc fat than themen (P 0.001 and P 0.002).
Palmitate rate of appearance, metabolic clearance rate, nonoxidative disposal rate, and oxidation
rate corrected for resting energy expenditure were greater in the women than the men (all P 
0.03). VLDL2-TG PR corrected for fat-freemass was higher in thewomen (P 0.001). VLDL2-TG and
VLDL2-cholesterol pools were higher in the women (P  0.001 and P  0.008). VLDL1-TG FCR and
PR and VLDL2-TG FCR were not different between genders.
Conclusion: Fatty acid and VLDL2-TG flux is higher in postmenopausal obesewomen than in obese
men matched for fasting plasma TG levels. (J Clin Endocrinol Metab 97: 2475–2481, 2012)
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High plasma triglycerides (TG) are independent andbetter predictors of cardiovascular disease (CVD)
than low-density lipoprotein (LDL) cholesterol in women
(1), suggesting that treatmentofhypertriglyceridemiamay
bemore important in women. This findingmay be related
to differences in lipid metabolism between genders.
Women are at a lower risk of cardiovascular disease than
men until they are postmenopausal, when the risk is sim-
ilar (2). The reason for this is not clear but may be related
to the increase in fat in postmenopausal women rather
than the loss of ovarianhormones (3).Obesity is oneof the
major risk factors for the development of CVD in both
men and women (4).
In young lean subjects, it has been shown that very-
low-density lipoprotein (VLDL)-TG production by the
liver is higher in women than men, but because clearance
was also much higher in women, this resulted in lower
plasma TG in women than men (5). In young obese men,
VLDL-TG production was higher than in young obese
women, and clearance was similar in the two groups, also
resulting in lower plasma TG in women than men (6).
Although these studies clearly indicate there are major
differences in lipoprotein metabolism inmen andwomen,
if we are to understand why plasma TG is a better pre-
dictor ofCVD inwomen,VLDLkinetics studies need tobe
undertaken in men and women matched for plasma TG
concentration.
VLDL secreted by the liver can be divided into the large
TG-rich VLDL1 and the smaller more dense TG-poor
VLDL2. There is evidence that these two VLDL species are
independently regulated (7).The first step inVLDLassembly
is the formation of a partially assembled primordial particle
(pre-VLDL). This is formed when apolipoprotein B100 is
cotranslationally lipidated in the endoplasmic reticulum by
microsomal transfer protein. Pre-VLDL can either be re-
tained and degraded or further lipidated to form VLDL2.
This particle is transported to theGolgi and can then either
be secreted or converted to the large TG-rich form,
VLDL1, after the addition of more TG. The hydrolysis of
VLDL1-TG by lipoprotein lipase also generates VLDL2.
Thus, VLDL2 has two sources.
All of the studies to date that have investigated
VLDL1-TG and VLDL2-TG kinetics have been in men (8,
9). VLDL1 and VLDL2 apolipoprotein B kinetics have
been investigated inmen andwomen combined in a single
group (10), but no studies have examined gender differ-
ences in VLDL1 and VLDL2 kinetics.
The regulation of VLDL production is governed partly
by the intracellular availability of lipid substrates for li-
poprotein assembly (11, 12). The production of free fatty
acids (FFA) from adipose tissue has been shown to be
greater in young leanwomen thanmen evenwhen they are
matched for adiposity (13). Although FFA concentrations
have been reported to be higher in women (14), the dif-
ference is small, and many studies find no difference in
FFA concentrations (15). This suggests that FFA clearance
from the circulation must also be higher in women than
men. The increased delivery of FFA to liver may lead to
increased VLDL-TG production in women.
Using stable isotope techniques, this study has inves-
tigated in postmenopausal obese women and men
matched for age, body mass index (BMI), and fasting
plasma TG whether there are differences in VLDL1-TG
and VLDL2-TG production and clearance rate, FFA
production, and oxidation rate.
Subjects and Methods
Study design
This study was approved by the East Kent Ethics Committee
and University of Surrey Ethics Committee. Written informed
consent was provided by all subjects before inclusion in the
study. Subjects were excluded if they were diagnosed with dia-
betesor suffering fromeither cardiovascularor endocrinedisease
or hepatic or renal disorders. Exclusion criteria also included the
prescribed use of anymedications known to alter bodyweight or
appetite, -blockers, fibrates, and metformin.
Eight obese men (60 3 yr, BMI 32 1 kg/m2) (mean
SEM) and 10 postmenopausal obese women (58  2 yr, BMI 
33 1 kg/m2) with fasting plasma TG no higher than 1.7mmol/
liter participated in the study. Measurement of 1) resting en-
ergy expenditure (REE) and the acetate correction factor and
2) palmitate and TG kinetics were measured on two separate
study days. Body composition was measured by magnetic res-
onance imaging. Subjects were asked not to undertake any
vigorous exercise or drink any alcohol for 48 h before both
study days. Subjects were provided with a standardized low-
fat, low-fiber meal the evening before both study days and
then fasted overnight.
Study 1
Twenty-four-hour urine samples were collected the previous
day for the measurement of nitrogen excretion. REE and fat and
carbohydrate oxidation were measured using a ventilated hood
open-circuit indirect calorimeter (gas exchange monitor; GEM-
Nutrition Ltd., Cheshire, UK). Subjects were allowed to rest for
30 min in a quiet room and completed three practice measure-
ments to avoid a training effect. A 40-min measurement of REE
was then made. This was followed by a priming dose of [1-
13C]sodium bicarbonate (0.085 mg/kg) and a 2-h infusion of
[1,2-13C]acetate (0.08 mol/kg  min) via an indwelling venous
cannula. Measurements of 13CO2 production rate (PR) were
made to correct palmitate oxidation for the loss of label in the
tricarboxylic acid cycle (16). Breath samples were collected at
baseline and then every 10 min from 90–120 min for the mea-
surement of 13CO2. CO2 PR was measured with the gas ex-
change monitor.
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Study 2
Study 2 took place 3 d after study 1. A baseline blood sample
was taken tomeasure the baseline enrichment and concentration
of plasma palmitate and the glycerol enrichment of VLDL1- and
VLDL2-TG. A baseline breath sample was taken to measure the
baseline enrichment of 13CO2. An iv bolus of [1,1,2,3,3-
2H5]glycerol (75mol/kg)wasadministered tomeasureVLDL1-
and VLDL2-TG metabolism. Blood samples were taken at in-
tervals for 7 h to measure glycerol enrichment of VLDL1- and
VLDL2-TG. A priming dose of [
13C]sodium bicarbonate (0.64
mg/kg) and a constant iv infusion of [U-13C]palmitate bound to
human albumin (5%) (0.01mol/kg min)was administered via
an indwelling venous cannula for 2 h to measure the palmitate
production and oxidation rate. Blood and breath samples were
taken every 10min from90–120min for themeasurement of the
enrichment and concentration of plasma palmitate and breath
13CO2. CO2 PR was measured with the gas exchange monitor.
Body composition
Ona separate day, adipose tissue content, intrahepatocellular
lipid (IHCL), and intramyocellular lipid (IMCL) were measured
at the Medical Research Council Clinical Sciences Centre Ham-
mersmith Hospital. Subjects fasted for 6 h before the scans.
Whole-body magnetic resonance imaging of body fat content
and IHCL and IMCL levels were acquired on an Intera 1.5-T
Achievamultinuclear system (PhilipsMedical Systems, Best, The
Netherlands) as previously reported (17). IMCL spectra were
obtained from the tibialis muscle group, which contains pre-
dominantly glycolytic fibers and soleus muscle. Total and re-
gional adipose tissue volumes were measured after imaging data
were analyzed using the SliceOmatic image analysis program
(Tomovision, Montreal, Quebec, Canada). All spectra were an-
alyzed in the time domain using the AMARES algorithm in-
cluded in theMRUI software package (18). IMCLwas expressed
as a ratio to the muscle creatine signal. IHCL was expressed as
a ratio to liver water content.
Laboratory methods
VLDL1 (Svedberg flotation rate 60–400) and VLDL2 (Sved-
berg flotation rate 20–60) were separated by sequential ultra-
centrifugation as described previously (19). VLDL1- and
VLDL2-TGwere extractedwith chloroform-methanol (2:1), iso-
latedby thin layer chromatography, andhydrolyzed in a solution
of 2% HCl in methanol, and the liberated glycerol was purified
by ion exchange chromatography and derivatized to form the
triacetate derivative (20). Isotopic enrichment was measured by
positive chemical ionization gas chromatography mass spec-
trometry (GCMS) (Agilent 5973 networkMSD) monitoring the
ions 159 and 164. FFA were extracted from plasma and deriva-
tized to their methyl esters. The isotopic enrichment of the
palmitic acid methyl ester was measured by GCMS monitoring
the ions 270 and 286. CO2 enrichment wasmeasured by isotope
ratio MS (Delta XP, coupled with a Gas Bench II; ThermoElec-
tron, Bremen, Germany). Plasma palmitate concentration was
measured by GCMS after addition of an internal standard, hep-
tadecanoic acid.
Urine nitrogen concentration was measured with a LECO
model FP-428 nitrogen analyzer (LECO Corp., St. Joseph, MI).
Enzymatic assays were used to measure plasma FFA, total cho-
lesterol, TG, 3-hydroxybutyrate, VLDL1- and VLDL2-TG
(ABX; Chicksands, Shefford, Bedfordshire, UK), and glycerol
(Randox Laboratories, Antrim, Northern Ireland, UK) using a
Cobas MIRA (Roche, Welwyn Garden City, UK). High-density
lipoprotein (HDL)-cholesterol was measured enzymatically af-
ter precipitation of apolipoprotein B-containing proteins with
dextran sulfate/magnesium chloride using a stable liquid re-
agent-immunoinhibition method (HDL-C L-Type, Alpha Labs,
Eastleigh,Hampshire,UK). Insulin, adiponectin, and leptinwere
measured by immunoassay using commercially available kits
(Millipore Corp., Billerica, MA).
Data analysis
Tracer enrichment of palmitate, glycerol, and CO2 was ex-
pressed as tracer-to-tracee ratio (TTR) corrected for baseline
enrichment. Palmitate rate of appearance (Ra) was calculated as
infusion rate of tracer/TTR. Palmitate Ra was assumed to equal
the rate of disappearance (Rd). Palmitate metabolic clearance
rate (MCR) was calculated by dividing palmitate Rd by palmi-
tate concentration. The PR of 13CO2 from the infused palmitate
tracer was calculated as CO2 TTR  VCO2/k.Ac_recovery
where VCO2 is carbon dioxide production (liters per minute), k
is the volume of 1 mol CO2 (22.4 liters), and Ac_recovery is the
fractional 13C label recovery in breath CO2, observed after the
infusion of labeled acetate (16) and calculated as CO2 TTR 
VCO2/k.2F, where F is the infusion rate of [1,2-
13C]acetate.
Plasma palmitate oxidation was calculated as palmitate Rd 
(13CO2 PR/F 16) where F is the palmitate infusion rate and 16
is thenumberof carbonatoms inpalmitate. Plasmanonoxidative
disposal was calculated as the difference between palmitate Rd
andpalmitate oxidation rate. Palmitate kineticswas expressed in
terms of both REE and fat-free mass (FFM). The latter was cal-
culated as the difference between bodyweight and total body fat
measured by magnetic resonance imaging. VLDL1- and
VLDL2-TG fractional catabolic rate (FCR) was calculated using
a compartmentmodel ofVLDL1-TGandVLDL2-TGkinetics (8)
using the SAAM II program (SAAM Institute, Seattle, WA). The
model represents the kinetics of the TTR profiles, which change
as labeled glycerol is removed from plasma and incorporated
into the TG fractions. The model assumes steady state of native
(unlabeled) glycerol throughout the experimental period, i.e. a
constant appearance, disappearance, and incorporation of na-
tive glycerol into the TG fractions. The incorporation of glycerol
into VLDL by the liver is subject to a delay, and two delay path-
ways were represented (21). Themodel included a compartment
forVLDL1-TGanda compartment forVLDL2-TGwith an input
into both compartments from the glycerol precursor pool, a loss
from each compartment,and a transfer from the VLDL1-TG com-
partment to the VLDL2-TG compartment. The direct input into
VLDL2-TG is termedVLDL2-TG hepatic PR, whereas the transfer
fromVLDL1-TGintoVLDL2-TGis termedVLDL1- toVLDL2-TG
transfer rate. Figure 1 shows a typical curve fit. VLDL1-TG and
VLDL2-TG PR (the sum of VLDL2-TG hepatic PR andVLDL1- to
VLDL2-TG transfer rate) were calculated as the product of
VLDL1-TG and VLDL2-TG FCR and their respective TG pool.
VLDL1- and VLDL2-TG pools were calculated from VLDL1- and
VLDL2-TG concentration and plasma volume, which was deter-
minedbythemethodofPearsonetal. (22).TotalVLDL-TGPRwas
calculatedasthesumofVLDL1-TGPRandVLDL2-TGhepaticPR.
VLDL kinetics are expressed in terms of FFM.
Carbohydrate and fat oxidation were calculated from the
measurements of oxygen consumption and carbon dioxide pro-
duction corrected for protein oxidation, calculated from urinary
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nitrogen excretion, as described by Frayn (23). Fasting insulin
sensitivity was assessed by homeostatic model assessment of in-
sulin resistance (HOMA-IR) (24).
Statistical analysis
The results are presented as means  SEM. Differences be-
tween groups were analyzed by Student’s t test using SPSS (ver-
sion 16). Nonparametric data were logarithmically transformed
before analysis. Associations between variables of interest were
performed using correlation analysis.
Results
Body composition and energy expenditure
Body weight, FFM, and REE were higher in the men
(P 0.001, P 0.001, and P 0.001 respectively). Total
fat mass was not significantly different between genders,
but sc fat mass and abdominal sc fat were higher in the
women, (P  0.002 and P  0.05), whereas visceral fat
was lower (P 0.001). BMI, waist circumference, IHCL,
and IMCL were not different between genders. Total fat
and carbohydrate oxidation also did not differ between
genders (Table 1).
Hormones, lipids, and insulin sensitivity
Fasting serum insulin, plasma glucose, and HOMA-IR
were not different between genders. Leptinwas higher in the
women (P  0.001), but adiponectin was not different.
There was no difference in plasma TG, total cholesterol,
LDL, or HDL cholesterol. The concentration of 3-Hydroxy
butyrate was not different in men and women (Table 2).
Palmitate kinetics
Although FFA concentrations were higher in the
women, thiswas not statistically significant.Glycerol con-
centrations were markedly higher (P  0.001) compared
with the men. Palmitate flux, MCR, and oxidation rate
were significantly higher in the women than men ex-
pressed as FFM (P 0.004, P 0.005, and P 0.002) or
REE (P  0.02, P  0.03, and P  0.03). The higher
palmitate oxidation rate in the women only partially ac-
counted for the higher palmitate flux; thus, there was also
a higher palmitate nonoxidative disposal in the women
compared with the men expressed as FFM or REE (P 
0.01 and P  0.03) (Table 3).
VLDL kinetics
TotalVLDL-TGPRwas 0.380.05 in thewomen and
0.300.04 in themen (not significantly different between
genders). The VLDL1-TG pool and VLDL1-TG FCR and
PR were also not significantly different between genders.
Plasma concentrations ofVLDL1-TGwere not different in
women (0.70  0.08 mmol/liter) and men (0.74  0.09
TABLE 2. Hormones, lipids, and insulin sensitivity
Men Women
P
values
Insulin (pmol/liter) 112.9  9.7 97.0  10.0 NS
Glucose (mmol/liter) 5.5  0.1 5.5  0.1 NS
HOMA-IR 2.1  0.3 1.8  0.2 NS
TG (mmol/liter) 1.17  0.10 1.21  0.07 NS
Cholesterol (mmol/liter) 5.2  0.3 5.6  0.2 NS
LDL cholesterol
(mmol/liter)
3.4  0.3 3.7  0.2 NS
HDL cholesterol
(mmol/liter)
1.24  0.10 1.36  0.06 NS
3-Hydroxybutyrate
(mmol/liter)
0.20  0.06 0.13  0.05 NS
Adiponectin (g/ml) 8.9  1.6 12.1  1.2 NS
Leptin ng/ml 8.8  1.1 21.2  2.2 0.001
NS, Not significant.
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FIG. 1. Typical curve fit using SAAM model in a female subject. f,
VLDL1; Œ, VLDL2. The solid lines indicate the curve fit.
TABLE 1. Body composition and energy expenditure
(mean  SEM)
Men Women
P
value
Age (yr) 60  3 58  2 NS
Body weight (kg) 104.2  4.7 85.4  2.2 0.001
BMI 32.0  0.3 32.6  0.6 NS
Waist (cm) 111.1  1.9 104.8  3.3 NS
Fat mass (kg) 35.8  2.4 41.3  1.6 NS
FFM (kg) 68.6  2.5 44.1  1.2 0.001
Visceral fat (kg) 5.7  0.5 3.5  0.3 0.001
sc fat (kg) 25.2  2.5 34.7  1.6 0.002
Abdominal sc fat (kg) 7.59  1.00 10.18  0.72 0.05
IHCL (%) 15.5  4.7 13.20  7.0 NS
Soleus IMCL 17.5  2.0 14.6  2.2 NS
Tibialis IMCL 9.4  0.9 7.8  0.7 NS
REE (kcal/d) 1912  77 1420  49 0.001
Carbohydrate oxidation
(mg/kg FFM  min)
2.75  0.22 2.91  0.22 NS
Fat oxidation
(mg/kg FFM  min)
0.66  0.10 0.70  0.11 NS
NS, Not significant.
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mmol/liter), but VLDL2-TG concentrations were signifi-
cantly higher in women thanmen (0.21 0.02 vs. 0.10
0.01; P  0.001). The VLDL2-TG pool and VLDL2-TG
PRwere significantly higher in thewomen (P0.001,P
0.001). The latter was due to both a higher hepatic pro-
duction of VLDL2-TG in the women than the men (P 
0.007) as well as a higher VLDL1- to VLDL2-TG transfer
rate in the women than the men (P 0.005). VLDL2-TG
FCRwas not significantly different between genders. The
VLDL1 cholesterol pool was not different between gen-
ders, but the VLDL2 cholesterol pool was higher in the
women (P  0.008). There was no correlation between
nonoxidative palmitate Rd andVLDL1-, VLDL2-, or total
VLDL-TG PR (Table 3).
Discussion
After the menopause, women have the same risk for
CVD as men. However, unlike men, in women, high
plasma TG are independent and better predictors of
CVD than LDL cholesterol (1). In this study, we inves-
tigated whether there were any differences in TG and
FFA kinetics between obese men and obese premeno-
pausal women matched for BMI, age, and fasting
plasma TG levels. Palmitate was selected to assess FFA
kinetics because it is one of the major FFA. The study
showed that obese postmenopausal women, with the
same fasting plasma TG level as men, have a higher fatty
acid flux relative to both FFMandREE thanmen and also
higherVLDL2-TGPRdue to both a higher hepatic PR and
a higher VLDL1- to VLDL2-TG transfer rate. Plasma fatty
acid oxidation was also higher in women than men, but it
did not fully account for the higher fatty acid flux so that
nonoxidative fatty acid Rd was also elevated.
FFA flux relative to FFMhas previously been shown to
be higher in postmenopausal women than men, although
the subjects were not age matched (25). This is the first
study to show this in obese age-matched postmenopausal
women and men. Nielsen et al. (15) showed in lean and
obese premenopausal women that FFA flux relative to
REE was 40% higher than in men of a similar BMI and
age. The current study also foundFFA flux relative toREE
was 40% higher in postmenopausal women than men,
suggesting that postmenopausal status does not affect the
gender difference in fatty acid flux. Although plasma FFA
oxidation was higher in women than men, total lipid ox-
idation, measured by indirect calorimetry, was not differ-
ent between genders,which suggests thatmenmayoxidize
more nonplasma lipids. Koutsari et al. (26)measured total
lipid oxidation by indirect calorimetry and subtracted this
from total FFA flux to obtain a measure of nonoxidative
FFA disposal in young men and women and also con-
cluded that nonoxidative FFA disposal was higher in
women. This increased flux could be an advantage at
times of increased fuel needs but could also lead to met-
abolic abnormalities such as increased intracellular
storage of TG in liver and muscle, which are associated
with insulin resistance (27, 28). Plasma FFA are a major
regulator of VLDL production with increased levels re-
sulting in an increase in VLDL-TG production (29).
TABLE 3. Palmitate and VLDL kinetics
Men Women P values
FFA (mol/liter) 681  64 798  51 NS
Glycerol (mol/liter) 62.8  7.3 128.1  8.6 0.001
Palmitate (mol/liter) 142.4  9.6 145.7  9.1 NS
Palmitate flux (mol/kg FFM  min) 2.93  0.28 4.53  0.35 0.004
Palmitate flux (mol/REE  min) 0.10  0.01 0.14  0.01 0.02
Palmitate MCR (mol/kg FFM  min) 21.11  2.24 31.41  2.11 0.005
Palmitate MCR (mol/REE  min) 0.74  0.06 0.99  0.08 0.03
Palmitate Ox (mol/kg FFM  min) 1.18  0.05 1.63  0.10 0.002
Palmitate Ox (mol/REE  min) 0.042  0.002 0.051  0.003 0.03
Palmitate non-Ox (mol/kg FFM  min) 1.75  0.20 2.90  0.29 0.01
Palmitate non-Ox (mol/REE  min) 0.062  0.008 0.090  0.008 0.03
VLDL1-TG pool (mol/kg FFM) 38.6  5.7 42.5  4.9 NS
VLDL2-TG pool (mol/kg FFM) 5.36  0.74 12.57  1.12 0.001
VLDL1 cholesterol pool (mol/kg FFM) 11.32  1.59 11.51  2.02 NS
VLDL2 cholesterol pool (mol/kg FFM) 3.39  0.60 7.10  0.98 0.008
VLDL1-TG FCR (pools/d) 11.18  0.93 12.17  0.80 NS
VLDL2-TG FCR (pools/d) 12.28  0.94 14.17  1.52 NS
VLDL1-TG PR (mol/kg FFM  min) 0.29  0.04 0.36  0.05 NS
VLDL2-TG PR (mol/kg FFM  min) 0.05  0.01 0.12  0.02 0.001
VLDL2-TG liver PR (mol/kg FFM  min) 0.009  0.002 0.024  0.004 0.007
VLDL1- to VLDL2-TG transfer (mol/kg FFM  min) 0.04  0.01 0.10  0.02 0.005
NS, Not significant; Ox, oxidation rate; non-Ox, nonoxidative Rd.
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There was no correlation between nonoxidative FFA dis-
posal and VLDL-TG PR. However, because a previous
study has shown that the splanchnic uptake of FFA in
healthy human subjects is only 27%of total FFA flux (30),
this lack of correlation is not surprising. Using this figure
for liver uptake of FFA, assuming that the percentage of
palmitate oxidized in the liver is the same as the whole
body and converting nonoxidative palmitate flux to non-
oxidative FFA flux, if all VLDL-TG production was syn-
thesized from imported FFA, this would account for 40%
of nonoxidative FFA flux to the liver in men and 27% in
women. However, this would be an overestimate because
it has been shown that only 77% of VLDL-TG is derived
from circulating fatty acids in the fasting state in healthy
subjects (31). The fate of the remaining nonoxidative flux
will include phospholipid synthesis and the esterification
of cholesterol. It is unknown whether the flux rates for
these differ in men and women.
Previous studies have shown VLDL-TG production by
the liver to be higher in youngobesemen than youngobese
women, and because VLDL-TG clearance was similar in
the two groups, this resulted in lower plasma TG in the
women (6). In our study, there was also no difference be-
tween genders in VLDL1- and VLDL2-TG FCR. Total
VLDL-TG PR was not different between genders. A pre-
vious study also reported that VLDL-TG PR was not dif-
ferent in postmenopausal obese women and men, al-
though the men had plasma TG that were almost 0.5
mmol/liter higher than the women (25).
It is clear from this study that in postmenopausal
women with the same plasma TG level as men, there is a
difference in VLDL2-TG kinetics. This was due to both a
higher hepatic VLDL2-TG PR and a higher transfer of
VLDL1-TG to VLDL2-TG. Women have been shown to
have higher lipoprotein lipase activity than men (32), and
this may account for the higher transfer rate. Insulin has
been shown to regulate the production of VLDL1 but not
VLDL2 (7), suggesting there is independent regulation of
these two VLDL particles. Although VLDL1 and VLDL2
apolipoprotein B concentration was not measured in our
study, the higher TG pool was matched by a higher cho-
lesterol pool inwomen; i.e. theTG to cholesterol ratiowas
similar in men and women, suggesting that there was an
increase in the number of VLDL2 particles. The mecha-
nism for the higher hepatic VLDL2 PR in women, which
was a relatively small proportion of total VLDL-TG pro-
duction, is not clear but may be related to the higher non-
oxidative FFA flux. Although it is widely recognized that
the availability of TG is an important regulator of VLDL
production (29), both in vivo and in vitro studies have
shown that cholesterol and/or cholesterol esters are also
an important regulator of VLDL production (33).
Whether the higher VLDL2-TG PR relates to themech-
anism for the higher risk of CVD in women with the same
TG level as men is not clear, but the higher VLDL2-TG PR
maygeneratemore intermediate-density lipoprotein (IDL)
and LDL. IDL levels have been shown to be associated
with the progression of atherosclerosis in humans (34).
Radioactively labeled VLDL2 has also been shown to be
efficiently converted toLDLwithmore than50%of tracer
found inLDLafter 24h,whereas only 10%ofVLDL1was
converted to LDL in the same time period (34). However,
despite the higher VLDL2-TG PR in our study, LDL cho-
lesterol was not different between genders. To gain a
greater understanding of why high plasma TG are inde-
pendent and better predictors of CVD in women, addi-
tional studies are needed tomeasure IDLandLDLkinetics
in women and men matched for plasma TG.
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